NCT05022758View on ClinicalTrials.gov

A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin

CompletedOBSERVATIONAL
Enrollment

45,000

Participants

Timeline

Start Date

October 6, 2021

Primary Completion Date

October 24, 2022

Study Completion Date

October 24, 2022

Conditions
Non-valvular Atrial Fibrillation (NVAF)
Interventions
DRUG

Rivaroxaban (Xarelto, BAY59-7939)

One of NOAC (Non-vitamin K antagonist oral anticoagulants)

DRUG

Warfarin

One of OAC (Oral anticoagulation therapy)

Trial Locations (1)

Unknown

Many locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT05022758 - A Study to Learn Whether There Are Differences in the Kidney's Ability to Work Properly in Korean Patients With Non-valvular Atrial Fibrillation (Irregular and Often Rapid Heartbeat Not Caused by a Heart Valve Problem) Treated With Rivaroxaban as Compared to Those Treated With Warfarin | Biotech Hunter | Biotech Hunter